NSCLC with C190 expression may inhibit the efficacy of anti-PD-L1 antibody and T-cell activation through increased sPD-L1, leading to immunotherapy resistance and poor outcome. The gene discussed is SPDL1; the disease is non-small cell lung carcinoma.